Fungal infections of the nail: New perspectives

International Journal of Lower Extremity Wounds

Volumn 4, Issue 2, 2005, Pages 72-73

  Bristow, Ivan ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; EDITORIAL; FOOT AMPUTATION; HUMAN; LEG AMPUTATION; MYCOSIS; ONYCHOMYCOSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SKIN INFECTION; SYMPTOM; TINEA PEDIS; DERMATOMYCOSIS; MICROBIOLOGY; NAIL DISEASE;

DERMATOMYCOSES; HUMANS; NAIL DISEASES;

EID: 23044486374     PISSN: 15347346     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534734605277057     Document Type: Editorial

References (16)

1. Burzykowski G, Molenberghs G, Abeck D, et al. High prevalence of foot diseases in Europe: results of the Achilles project. Mycoses 2003;46:496-505.
2. Yosipovitch G, Hodak E, Vardi P, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 1998;21:506-9.
3. Gupta A, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139:665-71.
4. Dogra S, Kumar B, Bhansali A, et al. Epidemiology of onychomycosis in patients with diabetes mellitus in India. Int J Dermatol 2002;41:647-51.
5. Gupta AK, Gupta MA, Summerbell RC. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000;14:466-9.
6. Maruyama R, Hiruma M, Yamauchi K, et al. An epidemiological and clinical study of untreated patients with tinea pedis within a company in Japan. Mycoses 2003;46:208-12.
7. Drake L, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998;38:702-4.
8. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. Br Med J 1999;318:1591-4.
9. Roldan Y, Mata-Essayag S, Hartung C. Erysipelas and tinea pedis. Mycoses 2000;43:181-3.
10. Semel J, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996;23:1162-4.
11. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10.
12. Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002;138:829-30.
13. Gupta AK, Ryder J, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004;150:537-44.
14. Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high risk populations and in patients with non-dermatophyte infections. Br J Dermatol 2004;150:414-20.
15. Sigurgeirsson B, Ólafsson JH, Steinsson J, et al. Long term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis. Arch Dermatol 2002;138:353-7.
16. Lambert J. Pharmacoeconomic issues in onychomycosis. Br J Dermatol 2003;49(Suppl 65):19-22.